GE Healthcare

PRESS RELEASE

GE HEALTHCARE TO PURCHASE ASSETS OF ONI MEDICAL SYSTEMS, INC., PROVIDER OF WORLD'S ONLY HIGH-FIELD DEDICATED EXTREMITY MRI SCANNERS

- ONI provides high-performance low-cost, dedicated extremity Magnetic Resonance Imaging (MRI) systems; can potentially help reduce patient backlog
- ONI's high-field scanners designed specifically for imaging of the extremities - exclusively configured to enclose only the joint being imaged
- Claustrophobic patients can sit comfortably for their MRI scan, with image quality comparable to whole-body scanners
- Aligned with GE's healthymagination vision around driving improvements in quality, access and cost; will enable more cost-effective imaging procedures in a variety of patient care settings

New York City, New York – **OCTOBER 21, 2009** – GE Healthcare, the US$ 17 billion healthcare business of General Electric Company (NYSE:GE) announced it has entered into an agreement to purchase certain assets of ONI Medical Systems, Inc., a privately held company headquartered in Wilmington, Massachusetts, USA. In line with GE's healthymagination vision, ONI's innovative products will expand GE Healthcare's Magnetic Resonance Imaging (MRI) capabilities, offering healthcare professionals a broader range of MRI products to enable more cost-effective imaging procedures in a variety of patient care settings. Financial terms were not disclosed.

ONI Medical Systems is a provider of high performance, low-cost, dedicated purpose MRI systems. This includes the MSK Extreme™ 1.0T and the MSK Extreme™ 1.5T, the world's only compact designed, high-field, truly open configuration extremity MRI systems available in the medical marketplace. ONI's scanners are designed specifically for imaging of the extremities - only the joint being imaged is inside of the scanner. ONI's products also have a small footprint for convenient siting in limited spaces and premium image quality, allowing clinicians' the same diagnostic confidence for extremity imaging at a lower cost when compared to a whole body MRI unit.

"One of the cornerstones of GE's healthymagination vision is to develop and invest in technologies that increase quality, improve access and decrease costs. In line with this vision, the addition of ONI's products enhances our Magnetic Resonance business. It gives us an opportunity to explore technologies that will

increase patient access for claustrophobic patients, products with a smaller footprint and premium image quality, and specialty systems that provide advanced, cost-effective MR patient imaging," said Jim Davis, vice president and general manager of GE Healthcare's global MR business.

Both MSK Extreme™ 1.0T and MSK Extreme™ 1.5T scanners are applicable to healthcare providers in hospitals, imaging centers and orthopedic/sports medicine practices where there is a need for an anatomy-specific MRI system that provides a quiet, comfortable, non-claustrophobic experience for patients. The current installed base of these two products is more than 175 units worldwide, including some of the top academic hospitals in the world.

"Through this transaction, GE Healthcare is acquiring an outstanding R&D team of engineers and scientists led by Dr. Peter Roemer, an International Society for Magnetic Resonance in Medicine's 2009 Gold Medal Award winner. We believe by combining the expertise and knowledge of these two businesses, we will create significant added value for our customers and patients everywhere," added Davis.

ONI's musculoskeletal MRI systems have a combination of features – high image quality, fast scan times, robust pulse sequences, and a small footprint. Even patients with extreme cases of claustrophobia are able to sit comfortably for their MRI scan, with no compromises in image quality compared to whole-body scanners. ONI MRI systems can be placed alongside other whole body MRI units in hospitals and imaging centers to reduce patient backlogs, or as the main system in orthopedic/ sports medicine offices that need fast, high quality, patient friendly MRI.

"As one of ONI's original founders and a co-inventor of the MSK Extreme scanners, I am very excited to join the GE team in offering our products to customers worldwide. Our product line is highly synergistic with GE's whole-body MR business. Our companies share a vision of providing innovative solutions for cost-effective, high-quality MR imaging. By joining GE Healthcare, we can combine our comprehensive product offerings and expand our global reach," said Peter Roemer, Chief Technology Officer at ONI.

"We commend ONI's vision and successful execution of building a specialized MRI instrument platform," commented Zubeen Shroff, Chairman of ONI Medical. "On behalf of the Galen Partners led investor syndicate that included Ivy Capital Partners and Ziegler Meditech Equity Partners, we are proud of ONI's accomplishments and are pleased these innovative devices will be part of GE's MRI offering."

The transaction is subject to customary closing conditions and is expected to close during the 4th quarter of 2009.

###

About ONI Medical Systems, Inc.
ONI Medical Systems, Inc. develops and markets dedicated-purpose musculoskeletal MRI systems that exceed the rigorous requirements of diagnostic radiology. With a clear focus on both image quality and clinical utility, ONI's product design addresses the strict needs of facilities with limited space and budgets, clinicians seeking superior diagnostic MR technologies, and patients who require a comfortable diagnostic testing experience. For more information, please visit www.onimri.com.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Media Contact:

GE Healthcare
America:
Arvind Gopalratnam
Cell: +1.262-501-0777
Arvind.Gopalratnam@ge.com

International:
GE Healthcare, Europe, Middle East & Africa
Sebastien Duchamp

GE Healthcare

Cell: +33.731.95964
Sebastien.Duchamp@ge.com

ONI Medical Systems
Cathleen Alaimo
Tel#: 781-262-5545
Cathleen@onicorp.com

GE Launches $250 Million Healthymagination Fund

New equity investment fund to invest in high potential healthcare technology companies; Supports GE's global Healthymagination initiative, focusing on cost, access and quality.

Fairfield, CT, USA – October 21, 2009 — GE (NYSE: GE) announced today the formation of the "GE Healthymagination Fund", a new equity fund that will make investments in highly promising healthcare technology companies. The fund will invest in companies globally that have innovative diagnostic, IT, and life sciences technologies aligned with the strategic objectives of GE's Healthymagination initiative. The fund will also support healthcare companies developing innovative and unique business models and services.

The formation of the fund is part of GE's $6 billion Healthymagination initiative, a global commitment to deliver better healthcare to more people at lower cost. The fund will target three broad areas for investment:

- **Broad-based Diagnostics**, including imaging, home health, patient monitoring, molecular diagnostics, pathology, novel imaging agents and other technologies for disease diagnosis.
- **Healthcare Information Technology**, including electronic medical records, clinical information systems, healthcare information exchanges and value-added data services.
- **Life Sciences**, including tools for research and development in biopharmaceuticals and stem cells, and technologies for manufacturing of biopharmaceuticals and vaccines.

The fund will draw on capabilities from across GE Healthcare, GE Capital and GE Global Research, and will have a global footprint.

"The creation of the GE Healthymagination Fund reaffirms our commitment to innovation in healthcare to bring better health to more people," GE Chairman and CEO Jeffrey Immelt said. "As GE works on solutions to healthcare's biggest challenges, it is vitally important that we support the development of companies with promising technologies or business models that are aligned with our strategy and have the potential to shape the future of healthcare. This includes smarter processes and technologies that measurably increase access to healthcare, reduce the cost of delivery and improve quality. The Healthymagination Fund gives us an opportunity to work with emerging companies to support their development, as well as provide them access to our technology base and our global presence."

"GE is able to offer a unique proposition to promising healthcare companies," Immelt said. "In addition to providing growth capital and investment expertise, through this fund we offer

entrepreneurs the opportunity to work directly with a global leader in healthcare technology in areas of mutual interest."

For further information about the fund, visit www.healthymaginationfund.com.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website www.gehealthcare.com.

About GE Global Research

GE Global Research is one of the world's most diversified industrial research organizations, providing innovative technology for all of GE's businesses. Global Research has been the cornerstone of GE technology for more than 100 years, and is now focused on developing breakthrough innovations in areas such as molecular medicine, energy conversion, nanotechnology, advanced propulsion and security technologies. GE Global Research is headquartered in Niskayuna, New York and has facilities in Bangalore, India; Shanghai, China; and Munich, Germany. Visit GE Global Research at www.ge.com/research.

About GE Capital

GE Capital offers consumers and businesses around the globe an array of financial products and services. For more information, visit www.gecapital.com. GE (NYSE: GE) is Imagination at Work - a diversified technology, media and financial services company focused on solving some of the world's toughest problems. For more information, visit the company's Web site at www.ge.com.

Contacts:

Fund

Sherwood Dodge
President & CEO
GE Capital, Equity
+1 203 956 4413
healthymaginationfund@ge.com

Michael A. Jones
Executive Vice President, Business Development
GE Healthcare
+1 203 956 4413
healthymaginationfund@ge.com

Media

Ned Reynolds
GE Capital Americas
+1 203 229 5717
ned.reynolds@ge.com

Michael Goodbody
GE Capital Europe
+44 7899 808 239
michael.goodbody@ge.com

Roger Pua
GE Capital Asia Pacific
+65 9653 3590
roger.pua@ge.com

Arvind Gopalratnam
GE Healthcare Americas
+1 262 501 0777
arvind.gopalratnam@ge.co

Dr. Val Jones
GE Healthcare worldwide
+44 7917 175 192
val.jones@ge.com

GE AND LILLY ACHIEVE SIGNIFICANT ADVANCEMENT IN CANCER RESEARCH

- **Companies develop technology to visualize and map complex biomarker networks**
- **Discovery could enable faster drug development at less cost, provide more personalized therapies**
- **Extension of molecular pathology research agreement planned**

New York, NY and Indianapolis, IN – October 21, 2009 – Scientists at GE Global Research (NYSE: GE), and researchers at Eli Lilly and Company (NYSE: LLY) today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.

Working together, the research teams have developed tissue-based biomarker technology that for the first time can simultaneously map more than 25 proteins in tumors at the sub-cellular level, an important step in the development of personalized and more effective cancer treatments. GE Chairman and CEO, Jeff Immelt, made the announcement this morning during a news conference at GE's Healthymagination Showcase in New York.

Currently, a diagnosis of cancer and the decision of which therapy to prescribe are based on the histology of the tumor and, in some cases, the expression of just one or two biomarkers inside the patient's tumor. With this new molecular pathology technology developed in GE's Biosciences laboratories, researchers can now look at a visual map of the tissue sample, seeing a cancer cell's comprehensive biomarker signaling pathway, and the interplay of signaling networks inside the tumor. To date, the new technology has been tested successfully on colon and prostate cancer tissue samples and is believed to be applicable to all types of cancer.

Mapping a tumor's complex biomarker network could allow researchers involved in drug discovery and the clinicians making treatment decisions to identify the most effective cancer therapies for patients, while avoiding those that are not as effective, saving time, money and providing a better patient experience.

"This new approach to molecular pathology unlocks information that has been hidden from doctors," said Mark Little, senior vice president and director, GE Global Research. "It was just two years ago that researchers at GE and Lilly set out to discover key protein biomarkers that would predict the likelihood that a medication would be

- MORE -

effective in treating certain cancers. Our new mapping technology is designed to bring new therapies to market faster and to make sure that the right patients get the right medicines."

GE researchers with specialties in biology, bioinformatics, optics, fluidics, chemistry and mechanical engineering have built a prototype system capable of staining, washing and re-staining tissue samples for study under a digital microscope. The system combines image analysis of cancerous cells and structures with GE's patented visualization tools to provide a color map of protein concentrations within the sample.

"In cancer treatment, information is one of the most powerful tools that a doctor has at his disposal," explained Dr. Richard Gaynor, vice president, cancer research and clinical investigation, Lilly Research Laboratories. "By identifying multiple biomarkers on a cell by cell basis, physicians will be able to make more informed choices on therapies to prescribe, as well as therapies to avoid, based on a patient's specific type of cancer. Additionally, we believe that GE's technology, advanced as a result of this collaboration, may lead to the ability to identify the stem cells within a tumor that we believe control the cancer. In doing so, we may be able to discover even more innovative, targeted therapies for the treatment of patients with cancer."

In May, GE launched Healthymagination, which is built on the global commitments of reducing costs, improving quality and expanding access to healthcare for millions of people. Technology development programs at GE Global Research, including the molecular pathology initiative, are aligned with this mission.

As the world becomes more educated and advanced in molecular medicine, the healthcare industry is experiencing a growing convergence of therapeutics and diagnostics. By using the advanced molecular pathology imaging tools developed in this collaboration, companies like Lilly can use the complex molecular signatures within patient tumors to design clinical research programs to study if these biomarkers can predict which patients are most likely to respond to a particular targeted therapy. Selecting the proper patients early, using these advanced technologies, could reduce the patient population sizes necessary for conducting clinical trials and will substantially shorten clinical development timelines. In turn, these changes should also lead to a reduction in the cost of drug development.

At today's news conference, GE and Lilly representatives also announced plans to extend their research agreement to include the study of four Lilly oncology molecules that are currently in the company's development pipeline. While the technology is expected to help in the analysis of all cancers, the two companies will perform specific investigations in breast, ovarian, lung, and possibly gastric cancers.

- MORE -

About GE Global Research
GE Global Research is one of the world's most diversified industrial research labs, providing innovative technology for all of GE's businesses. Global Research has been the cornerstone of GE technology for more than 100 years, developing breakthrough innovations in areas such as medical imaging, energy generation technology, jet engines and lighting. GE Global Research is headquartered in Niskayuna, New York and has facilities in Bangalore, India, Shanghai, China and Munich, Germany. Visit GE Global Research at www.ge.com/research.

About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

# # #

Media Contacts:

Patrick Jarvis
GE Global Research
(518) 387-6284
(518) 698-7764
patrick.jarvis@ge.com

Christine Van Marter
Lilly
(317) 651-1473 office
(317) 554-7923 cell
vanmarterch@lilly.com

GE Foundation to Direct $25 Million Towards Increasing Access to Primary Care for Underserved U.S. Populations

New "Developing Health" initiative helps drive GE's 'healthymagination' commitment in targeted American communities; enabling better health through a focus on access

NEW YORK, NY.-- October 21, 2009-- Today, GE, the GE Foundation, the philanthropic organization of GE Company, and the GE Corporate Diversity Council announced "Developing Health," a new 3-year, $25 million program that provides grant funding and employee engagement to selected health centers across the United States which focus on delivering primary care and access to quality healthcare.

The program, which launches in New York City and is modeled after GE's successful philanthropic program "Developing Health Globally," aims to increase access to primary care for underserved populations by providing GE Foundation grants and GE employee volunteer capacity to select non-profit health centers in targeted communities in the United States.

"At a time when the topic of healthcare is such a priority for all Americans, the GE Foundation continues to improve the lives of others through their generosity," said Mayor Bloomberg. "They have been a solid partner in efforts to enhance the lives of countless New Yorkers. We are grateful for their recognition and generosity in supporting the hard work of New York City's public health clinics, and for their commitment to helping our City's residents in underserved communities get greater access to primary health care providers."

New York City is home to the first four health centers awarded grants as part of the program. Grants totaling one million dollars have been awarded to:

- Bedford Stuyvesant Family Health Center
- Urban Health Plan, Inc.
- Brownsville Multi-Service Family Health Center
- Charles B. Wang Community Health Center

"While the nation wrestles with the tough issues of healthcare reform for the country, the tens of millions of people who don't have access today can't wait," said John Rice, GE vice chairman. "We can make a real, positive difference by supporting health centers like Bedford Stuyvesant Family Health Center in the work that they do to serve the needs of their community."

"With GE resources and the commitment of our employees, we have been successful in driving real, sustainable improvement around the world through the Developing Health Globally program, " said Bob Corcoran, President of the GE Foundation. "Our aim here is to combine Foundation resources

with our human capital to improve access to quality healthcare in America, beginning in New York City."

In association with this new program, an expert Advisory Panel has been formed to work with the GE Foundation and representatives of the GE Corporate Diversity Council to assist with structure of the program and selection process, providing public health expertise.

"GE's Affinity Networks are passionate about the role they play as leaders in community outreach around the world," said Deborah Elam, GE's vice president and chief diversity officer. "In this new, U.S.-based effort, the African American Forum, Asian Pacific American Forum, Hispanic Forum and Women's Network, along with other employee groups, are teaming up to lead employee volunteer efforts to support the heroic work being done by health centers across the country."

"We are delighted to be one of the first community health centers selected as part of this important initiative," said Mr. Ulysses Kilgore III, president of the Bedford-Stuyvesant Family Health Center in Brooklyn, NY. "We have been on the front line of delivering access to our community for more than thirty years and we are excited that GE and the GE Foundation are bringing their resources to bear to address the critical issue of healthcare delivery in our nation's neighborhoods."

"When we launched healthymagination, GE made a commitment to help address healthcare access for the underserved population across the United States," said Mike Barber, GE's vice president for healthymagination. "We know that nearly 16% of the U.S. population is without health insurance and needs access to primary healthcare, with more than 9 million children uninsured in the United States. We can do better, and the 'Developing Health' program is a significant step in the right direction."

Under the program guidelines, the GE Foundation will provide grants to the selected health centers. Grant recipients will be selected based on criteria that include, but are not limited to, need, community impact, leadership, and willingness to partner with GE volunteers, transparency and accountability. The GE Foundation will not accept unsolicited requests for support. The first generation of "Developing Health" cities selected was based on local GE employee presence and GE Affinity Network robustness.

The "Developing Health" program builds on the success of the existing Developing Health Globally (DHG) program. Launched in Africa in 2004 with the support of the GE Foundation and GE's Affinity Networks, DHG now extends to 14 countries across Africa, Latin America and Southeast Asia. DHG aims to improve access to quality healthcare for some of the world's most vulnerable populations. DHG uses GE core competencies including technology, expertise and employee engagement to offer sustainable "enterprise solutions" to address some of the critical gaps that exist in developing-world healthcare facilities. For more information on Developing Health Globally, visit: http://www.ge.com/citizenship/performance_areas/communities_philanthropy_health.jsp

About the GE Foundation

The GE Foundation, the philanthropic organization of the General Electric Company, works to solve some of the world's most difficult problems. In coordination with its partners, it supports U.S. and international education, developing health globally, the environment, public policy, human rights and disaster relief. In addition, the GE Foundation supports GE employee and retiree giving and involvement in GE communities around the world. In 2008, the entire GE family — including businesses, employees, retirees and GE Foundation — contributed more than an estimated $237 million to community and educational programs, including more than $100 million from GE Foundation. For more information, visit www.gefoundation.com.

About GE

GE (NYSE: GE) is a diversified infrastructure, finance and media company taking on the world's toughest challenges. From aircraft engines and power generation to financial services, medical imaging, and television programming, GE operates in more than 100 countries and employs about 300,000 people worldwide. For more information, visit the company's Web site at www.ge.com.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Healthymagination is a $6 billion commitment that was launched in May 2009.

PRESS CONTACTS

Frank Mantero
+1 203 373 3534, + 1 203 612 0603
frank.mantero@ge.com

Jeff DeMarrais
+1 203 373 3244, + 1 203 583 2495
Jeffrey.DeMarrais@ge.com